Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Michielin O"'
Autor:
Castelo Blanco L, Tsourti Z, Gennatas S, Rogado J, Sekacheva Marina, Viñal D, Lee R, Croitoru A, Vitorino M, Khallaf F, Šušnjar Snežana, Soewoto W, Cardeña A, Djerouni M, Rossi M, Alonso-Gordoa T, Ngelangel C, Whisenant JG, Choueiri TK, Dimopoulou G, Pradervand S, Arnold D, Harirngton K, Michielin O, Dafni U, Pentheroudakis G, Peters S, Romano E
Publikováno v:
ESMO open. 7(3)
Background:ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with
Autor:
Richtig, E., Loquai, C., Forschner, A., Gutzmer, R., Hassel, J. C., Utikal, J. S., Haferkamp, S., Meier, F., Debus, D., Dummer, R., von Moos, R. A. F., Thompson, J., Gengenbacher, L., Michielin, O., Höller, C., Schadendorf, Dirk
Poster-Abstract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=unidue___bib::4559d2d7bc4d4e78fd6ecba05d5c5573
Background: ESMO COVID-19 and CAncer REgistry (ESMO-CoCARE) is an international collaborative registry-based, cohort study gathering real-world data from Europe, Asia/Oceania and Africa on the natural history, management and outcomes of patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::4dd82c5f2962136171a6ed76b9a5098f
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3219295
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3219295
Autor:
Garassino, M.C., Whisenant, J.G., Huang, L.C., Trama, A., Torri, V., Agustoni, F., Baena, J., Banna, G., Berardi, R., Bettini, A.C., Bria, E., Brighenti, M., Cadranel, J., Toma, A. De, Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti, R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., Verde, N. La, Liu, S.V., Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G., Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L., Wu, Y.L., Zai, S., Pancaldi, V., Dingemans, A.M., Meerbeeck, J. Van, Barlesi, F., Wakelee, H., Schuurbiers, O.C.J., Peters, S., Horn, L.
Publikováno v:
Lancet oncology, 21(7), 914-922. Elsevier Science
Lancet Oncology, 21(7), 914-922. Lancet Publishing Group
The Lancet. Oncology, vol. 21, no. 7, pp. 914-922
Lancet Oncology, 21, 7, pp. 914-922
The lancet oncology
The Lancet. Oncology
Lancet Oncology, 21, 914-922
The Lancet Oncology
Lancet Oncology, 21(7), 914-922. Lancet Publishing Group
The Lancet. Oncology, vol. 21, no. 7, pp. 914-922
Lancet Oncology, 21, 7, pp. 914-922
The lancet oncology
The Lancet. Oncology
Lancet Oncology, 21, 914-922
The Lancet Oncology
Contains fulltext : 229846.pdf (Publisher’s version ) (Closed access) BACKGROUND: Early reports on patients with cancer and COVID-19 have suggested a high mortality rate compared with the general population. Patients with thoracic malignancies are
Publikováno v:
Cancer treatment reviews, vol. 100, pp. 102282
Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare immune related adverse event (irAE) with an estimated lethality of 50%. BRAFi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::e4423791360cfff8c6054a04a18ff434
https://serval.unil.ch/notice/serval:BIB_63661F460346
https://serval.unil.ch/notice/serval:BIB_63661F460346
Autor:
Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M.C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J.P., Michielin, O., Peters, S., Tabernero, J., Douillard, J.Y., Pentheroudakis, G.
Publikováno v:
Annals of oncology, vol. 31, no. 10, pp. 1320-1335
We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::510fb2dd937f9f5096f362f74014c082
https://serval.unil.ch/resource/serval:BIB_957BAED3FD8F.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_957BAED3FD8F.P001/REF.pdf
Autor:
Lopes, A. M. D. S., Colomer-Lahiguera, S., Mederos-Alfonso, N-N., Lopez, V. Aedo, Spurrier-Bernard, G., Tolstrup, L. K., Pappot, H., Aspeslagh, S., Rogiers, A., Neyns, B., Haanen, J. B. A. G., Mitchell, S. A., Addeo, A., Michielin, O. A., Eicher, M.
Publikováno v:
Lopes, A M D S, Colomer-Lahiguera, S, Mederos-Alfonso, N-N, Lopez, V A, Spurrier-Bernard, G, Tolstrup, L K, Pappot, H, Aspeslagh, S, Rogiers, A, Neyns, B, Haanen, J B A G, Mitchell, S A, Addeo, A, Michielin, O A & Eicher, M 2021, ' Selecting patient-reported outcomes to monitor symptomatic toxicities of immune-checkpoint inhibitors: A Delphi study ', Annals of Oncology, vol. 32, no. Suppl. 5, 1686P, pp. S1180 . https://doi.org/10.1016/j.annonc.2021.08.1658
Background: Immune-related Adverse Events (IrAEs) present a new challenge to patient safety. The use of Patient-Reported Outcomes (PROs) to monitor adverse events is increasing. Existing measures like the PRO version of the Common Terminology Criteri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a2408daf0ee6f14687c93c1fc0ed3542
https://biblio.vub.ac.be/vubir/selecting-patientreported-outcomes-to-monitor-symptomatic-toxicities-of-immunecheckpoint-inhibitors-a-delphi-study(b99b8fb7-4dce-4f0f-b368-3597a72fa2c3).html
https://biblio.vub.ac.be/vubir/selecting-patientreported-outcomes-to-monitor-symptomatic-toxicities-of-immunecheckpoint-inhibitors-a-delphi-study(b99b8fb7-4dce-4f0f-b368-3597a72fa2c3).html
Autor:
Jankovic, J., Da Silva Lopes, A.M., Morez, A., Darnac, C., Demicheli, R., Dalla-Vale, M., Lauriers, N., Garcia Sanchez, J., Bouchaab, H., Ninane, F., Peters, S., Michielin, O., Pradervand, S., Eicher, M., Colomer-Lahiguera, S.
Publikováno v:
Revue medicale suisse, vol. 17, no. 733, pp. 703-707
Compared with the general population, oncology patients face a higher morbidity and mortality caused by the COVID-19 pandemic. As a result, health systems had to quickly adapt cancer care in order to maintain the best quality and patient safety. From
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::69440a998328287525199956de2c89a5
https://serval.unil.ch/resource/serval:BIB_B502B1BCD7F4.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_B502B1BCD7F4.P001/REF.pdf
Publikováno v:
Revue medicale suisse, vol. 17, no. 732, pp. 635-639
In 2020, we have seen patients with neglected skin cancer in the context of the COVID pandemic. But what is the global health impact of the pandemic on skin cancer patients ? Is it as high as the delayed care of a heart infarct ? To answer this quest
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1900::587adb69a03956034c02d5ef081d6aa4
https://serval.unil.ch/notice/serval:BIB_729DC505DFD7
https://serval.unil.ch/notice/serval:BIB_729DC505DFD7